Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

BACKGROUND: It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment failure with imatinib. DESIGN AND METHODS: To add...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ibrahim, Amr R., Clark, Richard E., Holyoake, Tessa L., Byrne, Jenny, Shepherd, Pat, Apperley, Jane F., Milojkovic, Dragana, Szydlo, Richard, Goldman, John, Marin, David
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2011
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3232259/
https://ncbi.nlm.nih.gov/pubmed/21859733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049759
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires